Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05553522 · ClinicalTrials.gov registry record · Phase 1
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
A Phase 1 study, sponsored by Baptist Health South Florida.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT05553522 is a Phase 1 study that was terminated before completion, run by Baptist Health South Florida. The registered enrollment target is 1 participants.
The verdict
NCT05553522, a Phase 1 study, was terminated before completion, sponsored by Baptist Health South Florida.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab. The combined use of SRS with the three drugs is considered investigational.
Interventions
- COMBINATION_PRODUCT Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2025-12-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05553522
The ClinicalTrials.gov registry entry for NCT05553522 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baptist Health South Florida, which has 40 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine is the first listed.
NCT05553522 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05553522 about?
NCT05553522 is a clinical study titled "Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer". This research study will evaluate how well brain metastases associated with HER-2 positive breast cancer can be controlled using a type of radiation known as stereotactic radiosurgery (SRS) when combined with three therapeutic agents, tucatinib, capecitabine, and trastuzumab. The combined use of SR...
What is the current status of trial NCT05553522?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-01-29. Estimated completion is 2025-12-17.
What interventions are being tested in trial NCT05553522?
The interventions under investigation include: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05553522?
This trial is sponsored by Baptist Health South Florida, which has 40 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.